TfR mAb-Cross-Linked Rituximab/MTX-PEG-PLL-PLGA Drug-Loaded Nanoparticles Enhance Anticancer Action in B Lymphocytes

Figure 3

The sustained release percentage of MTX- and Rituximab-loaded nanoparticles in vitro.